Hepatic Dysfunction Quantified by HepQuant DuO Outperforms Child‐Pugh Classification in Predicting the Pharmacokinetics of Ampreloxetine
Clinical Pharmacology & Therapeutics · 2024-07 · 116 (1) · 186-193
DOI: 10.1002/cpt.3265 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 23.04.2024. Verfasst von Jitendra Kanodia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Theravance Biopharma US, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Liver Diseases, Morpholines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Theravance Biopharma.
Abstract (Originalsprache)
HepQuant tests quantify liver function from clearance of deuterium‐ and 13C‐labeled cholates administered either intravenously and orally (SHUNT) or orally (DuO). Hepatic impairment studies have relied on clinical or laboratory criteria like Child‐Pugh classification to categorize the degree of hepatic dysfunction. We compared HepQuant tests with Child‐Pugh classification in predicting the pharmacokinetics of ampreloxetine. Twenty‐one subjects with hepatic impairment (8 Child‐Pugh A, 7 Child‐Pugh B, and 6 Child‐Pugh C), and 10 age‐ and sex‐matched controls were studied. The pharmacokinetics of ampreloxetine were measured after oral administration of a single dose of 10 mg. Disease severity index (DSI), portal‐systemic shunting (SHUNT%), hepatic reserve, and hepatic filtration rates (HFRs) were measured from serum samples obtained after intravenous administration of [24‐ 13 C]‐cholate and oral administration of [2,2,4,4‐ 2 H]cholate. Ampreloxetine plasma exposure (AUC 0‐inf ) was similar to controls in Child‐Pugh A, increased 1.7‐fold in subjects with Child‐Pugh B, and 2.5‐fold in subjects with Child‐Pugh C and correlated with both Child‐Pugh score and HepQuant parameters. The variability observed in ampreloxetine exposure (AUC 0‐inf ) in subjects with moderate (Child‐Pugh B) and severe hepatic impairment (Child‐Pugh C) was explained by HepQuant parameters. Multivariable regression models demonstrated that DSI, SHUNT%, and Hepatic Reserve from SHUNT and DuO were superior predictors of ampreloxetine exposure (AUC 0‐inf ) compared to Child‐Pugh score. HepQuant DSI, SHUNT%, and hepatic reserve were more useful predictors of drug exposure than Child‐Pugh class for ampreloxetine and thus may better optimize dose recommendations in patients with liver disease. The simple‐to‐administer, oral‐only DuO version of the HepQuant test could enhance clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Theravance Biopharma US, Inc., South San Francisco, California, USA.
- Custom DX Solutions LLC, Houston, Texas, USA.
- HepQuant LLC, Denver, Colorado, USA.
ORCID-Profile: Michael P McRae, Steve M Helmke, Gregory T Everson
Förderung
- Theravance Biopharma
Zitieren
APA
Kanodia, J., Giovinazzo, H., Yates, W., Bourdet, D. L., McRae, M. P., Helmke, S. M., & Everson, G. T. (2024). Hepatic Dysfunction Quantified by HepQuant DuO Outperforms Child‐Pugh Classification in Predicting the Pharmacokinetics of Ampreloxetine. Clinical Pharmacology & Therapeutics, 116(1), 186-193. https://doi.org/10.1002/cpt.3265
Vancouver
Kanodia J, Giovinazzo H, Yates W, Bourdet DL, McRae MP, Helmke SM, et al. Hepatic Dysfunction Quantified by HepQuant DuO Outperforms Child‐Pugh Classification in Predicting the Pharmacokinetics of Ampreloxetine. Clinical Pharmacology & Therapeutics. 2024;116(1):186-193. doi:10.1002/cpt.3265
BibTeX
@article{Kanodia2024,
author = {Kanodia, Jitendra and Giovinazzo, Hugh and Yates, Wayne and Bourdet, David L and McRae, Michael P and Helmke, Steve M and Everson, Gregory T},
title = {Hepatic Dysfunction Quantified by HepQuant DuO Outperforms Child‐Pugh Classification in Predicting the Pharmacokinetics of Ampreloxetine},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
volume = {116},
number = {1},
pages = {186--193},
doi = {10.1002/cpt.3265}
}
EUVIMED